OFLOFT™ 200

Ofloxacin is a second-generation fluoroquinolone antibiotic that exerts bactericidal activity by simultaneously inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. Both enzymes are critical for bacterial DNA replication, transcription, repair, and recombination.

DNA gyrase introduces negative supercoils into chromosomal DNA to relieve torsional stress during replication — without this activity, the DNA becomes overwound and replication halts. Ofloxacin traps the gyrase-DNA complex in a cleaved, intermediate state, causing irreversible double-strand DNA breaks that rapidly kill the bacterium. Topoisomerase IV is responsible for decatenating (separating) replicated chromosomes before cell division — inhibition of this enzyme prevents daughter cells from separating, causing lethal chromosomal entanglement.

By targeting both enzymes simultaneously, ofloxacin has two separate targets for resistance development, making single-step resistance mutations effectively non-viable. This dual-target mechanism, combined with ofloxacin's exceptional oral bioavailability (~98% — essentially equivalent to intravenous administration), broad tissue distribution, and excellent penetration into urine, prostatic tissue, lung, and gastrointestinal mucosa, makes it one of the most versatile antibiotic agents for outpatient management of moderate infections.

At 200mg per tablet, OFLOFT™ 200 delivers the standard adult ofloxacin dose across urological, gastrointestinal, ENT, and soft tissue indications.

OFLOFT™ 200 is indicated for moderate bacterial infections in adults caused by ofloxacin-susceptible organisms, particularly where excellent bioavailability, broad tissue penetration, and coverage of atypical organisms are clinically important.

Urinary Tract Infections: Uncomplicated and complicated UTIs, pyelonephritis, urethritis, and prostatitis caused by E. coli, Klebsiella, Proteus, and Pseudomonas aeruginosa. Ofloxacin achieves urine concentrations 20–50 times the MIC for most gram-negative uropathogens, making it particularly effective for UTIs.

Sexually Transmitted Infections: Uncomplicated gonorrhoea (as part of empirical STI regimens), non-gonococcal urethritis (Chlamydia trachomatis), and pelvic inflammatory disease as part of combination therapy.

Gastrointestinal Infections: Traveller's diarrhoea, Shigellosis, Salmonellosis, and typhoid fever where fluoroquinolone susceptibility is confirmed by local antibiogram data.

Respiratory Infections: Acute exacerbations of chronic bronchitis and community-acquired pneumonia with suspected atypical pathogen involvement.

ENT Infections: Chronic suppurative otitis media and complicated sinusitis caused by resistant gram-negative organisms.

Skin Infections: Moderate skin and soft tissue infections where gram-negative coverage is required alongside gram-positive organisms.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.